100 likes | 121 Views
<br>Olimab 60mg belongs to novel, fully human IgG2 monoclonal antibody especially to receptor activator of nuclear factor kappaligand (RANKL), restrain bone resorption markers in patients with a difference of metastatic tumors @ Apple pharmaceuticals
E N D
Olimab 60mg injection | Denosumab 60mg Apple pharmaceuticals Olimab60mg | Olimab 60mg injection | Denosumab 60mg | Denosumab 60mg tablet
Olimab 60mg injection (Denosumab) • Olimab60mg belongs to novel, fully human IgG2 monoclonal antibody especially to receptor activator of nuclear factor kappa-B ligand (RANKL), restrain bone resorption markers in patients with a difference of metastatic tumors • Chemically, it exists of 2 heavy and 2 light chains. Each light chain contains of 215 amino acids.
PRESCRIBED • Treatment for patients having postmenopausal women with osteoporosis at high risk for fracture. • Treatment for patients with increase bone mass in men at more risk for fracture getting androgen deprivation therapy for non-metastatic prostate cancer. • Treatment for patients having to increase bone mass in women at more risk for fracture
DOSAGE Giant Cell Tumor of bone : • 120mg SC, every 4 weeks with additional 120mg doses on days 8 and 15 of the 1st month treatment Olimab 60mg • Injection of drug should be done in upper arm, upper thigh or abdomen Hypercalcemia: • Dose of 120mg Olimab 60mg tablet given SC, every 4 weeks with additional 120mg doses on days 8 and 15 of the 1st month treatment Injection of drug should be done in upper arm, upper thigh or abdomen
MECHANISM • Olimab60mg tablet linked to RANKL, a protein which is specific for the formation, function and survival of osteoclasts, the cells necessary for bone resorption. • Olimab 60mg prohibits osteoclast formation, function and survival hence, reducing bone resorption and raising bone mass and strength of the bone. • Without aggregation in Olimab pharmacokinetics with duration was noticed upon multiple dosing of 60 mg SC administered once every 6 months.
PRECAUTION • Before to start treatment with Olimab, discuss with the doctor about any other regimens you are using (including over-the-counter drugs, vitamins, or herbal remedies). • Olimab injection may improve the negative effects of immuno-suppressants. Especially the risk for serious infections may be increased. • Not to receive any type of vaccination without your doctor's consultation while admonishingdenosumab.
DRUG INTERACTION • No formal drug-drug interaction with denosumab during trials. • When interacting with some anticancer drug, orthopedic drugs, vaccines will lead to risk of adverse effects can be increased
SIDE EFFECTS Common side effects for the patient taking Olimab 60mg as follows : • Fatigue, Muscle weakness, Phosphorus level reduced in blood, Nausea Less common side effects for patients taking Olimab : • Dyspnea, Hypocalcemia, Cough, Arthralgia, Limb pain, Eczema, Headache
STORAGE • Store at 2℃ to 8℃ in the original container, avoid freeze • Before to administration keep at room temperature • Olimab protect from direct light and heat.
Contact Us • phone No :9987711567 • Email :info@myapplepharma.com website • https://myapplepharma.com/olimab-60mg.php